TrialThoracic cancer2020

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.

Ma Honglian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.